Physician profile
Travis Blanton
NPI 1336776699
$2,264.81
in general payments reported to CMS, 2019-2025
21 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.17 · 2022: $18.96 · 2023: $363 · 2024: $919 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $581.30 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $351.47 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $313.14 | 2024-2025 | |
| Myriad Women'S Health, INC. | $193.29 | 2023 | Myrisk |
| Abbvie INC. | $191.53 | 2023-2024 | Vraylar, Qulipta |
| Sanofi-Aventis U.S. LLC | $123.66 | 2024 | |
| Daiichi Sankyo INC. | $122.06 | 2024-2025 | Injectafer |
| Ardelyx, INC. | $85.37 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $44.38 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $34.86 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $33.86 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.17 | 2021 | |
| Seqirus USA INC | $23.71 | 2025 | Fluad, Flucelvax |
| Alexion Pharmaceuticals, INC. | $18.96 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.96 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.58 | 2023 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $17.40 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $17.17 | 2025 | The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $15.70 | 2024 | Farxiga |
| Corium, LLC | $14.65 | 2025 | Azstarys |
| Amgen INC. | $14.59 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Blanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.